JUSTIN LANDE: Open Payments
NPI 1538542378 · DANVILLE, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,120 in 63 payments from 23 companies in 2025. Trend: 2023 $2,221 · 2024 $1,988 · 2025 $1,120
Food & beverage: $1,120
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 16 | $198 |
| GlaxoSmithKline, LLC. | 9 | $171 |
| Novo Nordisk Inc | 5 | $97 |
| Otsuka America Pharmaceutical, Inc. | 4 | $93 |
| Lilly USA, LLC | 5 | $91 |
| Verona Pharma, Inc. | 3 | $56 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $47 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $43 |
| Vanda Pharmaceuticals Inc. | 2 | $37 |
| C2N Diagnostics, LLC | 1 | $32 |
Products named: TRELEGY ELLIPTA, VRAYLAR, REXULTI, MOUNJARO, Ozempic, QULIPTA, Ohtuvayre, JARDIANCE.
Industry payments across KY — which companies pay providers there.
